Literature DB >> 9247567

Cyclosporin A interferes with the inducible degradation of NF-kappa B inhibitors, but not with the processing of p105/NF-kappa B1 in T cells.

R Marienfeld1, M Neumann, S Chuvpilo, C Escher, B Kneitz, A Avots, A Schimpl, E Serfling.   

Abstract

The transcription factor NF-kappa B controls the induction of numerous cytokine promoters during the activation of T lymphocytes. Inhibition of T cell activation by the immunosuppressants cyclosporin A (CsA) and FK506 exerts a suppressive effect on the induction of these NF-kappa B-controlled cytokine promoters. We show for human Jurkat T leukemia cells, as well as human and mouse primary T lymphocytes, that this inhibitory effect is accompanied by an impaired nuclear translocation of the Rel proteins c-Rel, RelA/p65 and NF-kappa B1/p50, whereas the nuclear appearance of RelB remains unaffected. CsA does not interfere with the synthesis of Rel proteins, but prevents the inducible degradation of cytosolic NF-kappa B inhibitors I kappa B alpha and I kappa B beta upon T cell activation. CsA neither inhibits the processing of the NF-kappa B1 precursor p105 to p50, nor does it "stabilize" the C-terminal portion of p105, I kappa B gamma, which is degraded during p105 processing to mature p50. These results indicate that CsA interferes with a specific event in the signal-induced degradation of I kappa B alpha and I kappa B beta, but does not affect the processing of NF-kappa B1/p105 to p50.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9247567     DOI: 10.1002/eji.1830270703

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  12 in total

Review 1.  Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer.

Authors:  Y Yamamoto; R B Gaynor
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  The Ca2+-dependent phosphatase calcineurin controls the formation of the Carma1-Bcl10-Malt1 complex during T cell receptor-induced NF-kappaB activation.

Authors:  Lysann Palkowitsch; Uta Marienfeld; Cornelia Brunner; Andrea Eitelhuber; Daniel Krappmann; Ralf B Marienfeld
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

3.  Proximal human FOXP3 promoter transactivated by NF-kappaB and negatively controlled by feedback loop and SP3.

Authors:  Paul Eckerstorfer; Michael Novy; Sebastian Burgstaller-Muehlbacher; Wolfgang Paster; Herbert B Schiller; Herbert Mayer; Hannes Stockinger
Journal:  Mol Immunol       Date:  2010-05-11       Impact factor: 4.407

4.  Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells.

Authors:  T Ichiyama; M Nishikawa; T Yoshitomi; S Hasegawa; T Matsubara; T Hayashi; S Furukawa
Journal:  Antimicrob Agents Chemother       Date:  2001-01       Impact factor: 5.191

5.  Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment.

Authors:  H Chan; D P Bartos; L B Owen-Schaub
Journal:  Mol Cell Biol       Date:  1999-03       Impact factor: 4.272

6.  Remission of refractory minimal change nephrotic syndrome after basiliximab therapy.

Authors:  Sung-Shin Park; Won-Ho Hahn; Sung-Do Kim; Byoung-Soo Cho
Journal:  Pediatr Nephrol       Date:  2009-02-26       Impact factor: 3.714

7.  Natural anti-inflammatory agents for pain relief.

Authors:  Joseph C Maroon; Jeffrey W Bost; Adara Maroon
Journal:  Surg Neurol Int       Date:  2010-12-13

8.  Novel inhibitors of the calcineurin/NFATc hub - alternatives to CsA and FK506?

Authors:  Matthias Sieber; Ria Baumgrass
Journal:  Cell Commun Signal       Date:  2009-10-27       Impact factor: 5.712

9.  Autoregulation of Th1-mediated inflammation by twist1.

Authors:  Uwe Niesner; Inka Albrecht; Marko Janke; Cornelia Doebis; Christoph Loddenkemper; Maria H Lexberg; Katharina Eulenburg; Stephan Kreher; Juliana Koeck; Ria Baumgrass; Kerstin Bonhagen; Thomas Kamradt; Philipp Enghard; Jens Y Humrich; Sascha Rutz; Ulf Schulze-Topphoff; Orhan Aktas; Sina Bartfeld; Helena Radbruch; Ahmed N Hegazy; Max Löhning; Daniel C Baumgart; Rainer Duchmann; Martin Rudwaleit; Thomas Häupl; Inna Gitelman; Veit Krenn; Joachim Gruen; Jochen Sieper; Martin Zeitz; Bertram Wiedenmann; Frauke Zipp; Alf Hamann; Michal Janitz; Alexander Scheffold; Gerd R Burmester; Hyun D Chang; Andreas Radbruch
Journal:  J Exp Med       Date:  2008-07-28       Impact factor: 14.307

10.  Alteration of TLR3 pathways by glucocorticoids may be responsible for immunosusceptibility of human corneal epithelial cells to viral infections.

Authors:  Yuko Hara; Atsushi Shiraishi; Takeshi Kobayashi; Yuko Kadota; Yuji Shirakata; Koji Hashimoto; Yuichi Ohashi
Journal:  Mol Vis       Date:  2009-05-08       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.